Sublingual  	Sublingual  	 JJ	B-NP
immunotherapy 	immunotherapy 	 NN	I-NP
:  	:  	 :	O
administration 	administration 	 NN	B-NP
,  	,  	 ,	O
dosages 	dosages 	 NN	O
,  	,  	 ,	O
use  	use  	 VBP	O
Allergen  	Allergen  	 JJ	B-NP
extracts  	extracts  	 NN	I-NP
for  	for  	 IN	I-NP
sublingual  	sublingual  	 JJ	I-NP
immunotherapy  	immunotherapy  	 NNS	I-NP
( 	( 	 -LRB-	O
SLIT 	SLIT 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
marketed  	marketed  	 VBN	O
by  	by  	 IN	O
several  	several  	 JJ	O
manufacturers 	manufacturers 	 NNS	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
administration  	administration  	 NN	B-NP
schedules  	schedules  	 NNS	I-NP
and  	and  	 CC	O
amount  	amount  	 NN	O
of  	of  	 IN	O
allergen 	allergen 	 NNS	B-NP
( 	( 	 -LRB-	I-NP
s 	s 	 LS	I-NP
)  	)  	 -RRB-	I-NP
quite  	quite  	 RB	O
variable  	variable  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
different  	different  	 JJ	O
products 	products 	 NNS	O
,  	,  	 ,	O
although  	although  	 IN	O
almost  	almost  	 RB	O
all  	all  	 RB	O
are  	are  	 VBP	O
standardized  	standardized  	 JJ	O
biologically  	biologically  	 NN	O
or  	or  	 CC	O
immunologically 	immunologically 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
allergen  	allergen  	 JJ	B-NP
extracts  	extracts  	 NN	I-NP
for  	for  	 IN	O
SLIT  	SLIT  	 NNP	O
are  	are  	 VBP	O
available  	available  	 JJ	O
in  	in  	 IN	O
two  	two  	 CD	O
main  	main  	 JJ	O
pharmaceutical  	pharmaceutical  	 JJ	B-NP
forms 	forms 	 NNS	I-NP
:  	:  	 :	O
solution  	solution  	 NN	B-NP
to  	to  	 TO	O
be  	be  	 VB	O
delivered  	delivered  	 VBN	O
by  	by  	 IN	O
drop-counters 	drop-counters 	 NNP	B-NP
,  	,  	 ,	O
pre-dosed  	pre-dosed  	 JJ	B-NP
actuators  	actuators  	 NNS	I-NP
( 	( 	 -LRB-	O
mini-pumps 	mini-pumps 	 NNP	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
disposable  	disposable  	 JJ	O
single-dose  	single-dose  	 JJ	B-NP
vials 	vials 	 NN	I-NP
;  	;  	 :	O
tablets  	tablets  	 NNS	O
with  	with  	 IN	O
appropriate  	appropriate  	 JJ	O
composition  	composition  	 NN	O
that  	that  	 WDT	O
allows  	allows  	 VBZ	O
a  	a  	 DT	O
slow  	slow  	 JJ	O
( 	( 	 -LRB-	O
1-2  	1-2  	 CD	O
minutes 	minutes 	 NNS	O
)  	)  	 -RRB-	O
dissolution  	dissolution  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
mouth  	mouth  	 NN	O
in  	in  	 IN	O
contact  	contact  	 NN	O
with  	with  	 IN	O
saliva 	saliva 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
Europe 	Europe 	 NNP	O
,  	,  	 ,	O
SLIT  	SLIT  	 NNP	O
is  	is  	 VBZ	O
prescribed  	prescribed  	 VBN	O
in  	in  	 IN	O
general  	general  	 JJ	O
for  	for  	 IN	O
one  	one  	 CD	O
or  	or  	 CC	O
a  	a  	 DT	O
few  	few  	 JJ	O
allergens 	allergens 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
mixtures  	mixtures  	 NNS	O
are  	are  	 VBP	O
less  	less  	 RBR	O
used 	used 	 VBN	O
,  	,  	 ,	O
though  	though  	 IN	O
there  	there  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
immunological  	immunological  	 JJ	B-NP
contraindication  	contraindication  	 NN	I-NP
to  	to  	 TO	O
give  	give  	 VB	O
multiple  	multiple  	 JJ	O
allergens 	allergens 	 NN	O
.  	.  	 .	O
SLIT  	SLIT  	 NNP	O
traditionally  	traditionally  	 RB	O
involves  	involves  	 VBZ	O
a  	a  	 DT	O
build-up  	build-up  	 NN	B-NP
phase  	phase  	 NN	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
maintenance  	maintenance  	 NN	B-NP
phase  	phase  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
top  	top  	 JJ	O
dose 	dose 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
build-up  	build-up  	 NN	B-NP
phase  	phase  	 NN	I-NP
has  	has  	 VBZ	O
usually  	usually  	 RB	O
the  	the  	 DT	O
duration  	duration  	 NN	O
of  	of  	 IN	O
4  	4  	 CD	O
-  	-  	 :	O
6  	6  	 CD	O
weeks 	weeks 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
patient  	patient  	 NN	O
must  	must  	 MD	O
start  	start  	 VB	O
with  	with  	 IN	O
the  	the  	 DT	O
lowest  	lowest  	 JJS	O
concentration  	concentration  	 NN	B-NP
and  	and  	 CC	O
gradually  	gradually  	 RB	O
increase 	increase 	 VB	O
,  	,  	 ,	O
using  	using  	 VBG	O
the  	the  	 DT	O
different  	different  	 JJ	O
dosage  	dosage  	 NN	B-NP
preparations 	preparations 	 NNS	I-NP
,  	,  	 ,	O
until  	until  	 IN	O
the  	the  	 DT	O
maintenance  	maintenance  	 NN	B-NP
dose  	dose  	 NN	I-NP
is  	is  	 VBZ	O
reached 	reached 	 VBN	O
.  	.  	 .	O
Rush  	Rush  	 NNP	O
and  	and  	 CC	O
ultra-rush  	ultra-rush  	 JJ	B-NP
inductions  	inductions  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
introduced 	introduced 	 VBN	O
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
that  	that  	 WDT	O
is  	is  	 VBZ	O
very  	very  	 RB	O
favorable 	favorable 	 JJ	O
.  	.  	 .	O
For  	For  	 IN	O
these  	these  	 DT	O
reasons  	reasons  	 NNS	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
an  	an  	 DT	O
updosing  	updosing  	 JJ	B-NP
phase  	phase  	 NN	I-NP
maybe  	maybe  	 RB	O
even  	even  	 RB	O
not  	not  	 RB	O
necessary 	necessary 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
no-updosing  	no-updosing  	 JJ	B-NP
approach  	approach  	 NN	I-NP
would  	would  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
a  	a  	 DT	O
treatment  	treatment  	 NN	O
that  	that  	 WDT	O
is  	is  	 VBZ	O
more  	more  	 RBR	O
patient-friendly  	patient-friendly  	 JJ	B-NP
and  	and  	 CC	O
convenient  	convenient  	 JJ	O
to  	to  	 TO	O
manage 	manage 	 VB	O
.  	.  	 .	O
Indeed 	Indeed 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
most  	most  	 RBS	O
recent  	recent  	 JJ	O
randomized  	randomized  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
no-updosing  	no-updosing  	 JJ	B-NP
regimen  	regimen  	 NN	I-NP
and  	and  	 CC	O
their  	their  	 PRP$	O
results  	results  	 NNS	O
in  	in  	 IN	O
term  	term  	 NN	O
of  	of  	 IN	O
safety  	safety  	 NN	O
were  	were  	 VBD	O
as  	as  	 IN	O
favorable  	favorable  	 JJ	O
as  	as  	 IN	O
the  	the  	 DT	O
studies  	studies  	 NNS	O
performed  	performed  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
traditional  	traditional  	 JJ	O
updosing  	updosing  	 JJ	B-NP
approach 	approach 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
currently  	currently  	 RB	O
recommended  	recommended  	 VBN	B-NP
duration  	duration  	 NN	I-NP
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
is  	is  	 VBZ	O
comprised  	comprised  	 VBN	O
between  	between  	 IN	O
3  	3  	 CD	O
and  	and  	 CC	O
4  	4  	 CD	O
years  	years  	 NNS	O
depending  	depending  	 VBG	O
on  	on  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
response  	response  	 NN	I-NP
in  	in  	 IN	O
single  	single  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
